ETF Holdings Breakdown of EXEL

Stock NameExelixis Inc
TickerEXEL(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS30161Q1040

News associated with EXEL

Exelixis (NASDAQ:EXEL) Shares Gap Up on Analyst Upgrade
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price gapped up prior to trading on Monday after Stephens upgraded the stock from an equal weight rating to an overweight rating. The stock had previously closed at $40.37, but opened at $49.43. Stephens now has a $60.00 price target on the stock, up from their previous […] - 2025-06-25 05:18:52
Exelixis (NASDAQ:EXEL) Reaches New 52-Week High After Analyst Upgrade
Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) reached a new 52-week high during trading on Tuesday after Stephens upgraded the stock from an equal weight rating to an overweight rating. Stephens now has a $60.00 price target on the stock, up from their previous price target of $29.00. Exelixis traded as high as […] - 2025-06-25 05:18:49
Blue Trust Inc. Increases Holdings in Exelixis, Inc. (NASDAQ:EXEL)
Blue Trust Inc. increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 15.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,976 shares of the biotechnology company’s stock after purchasing an additional 1,745 shares during the period. […] - 2025-06-22 08:22:52
Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Farther Finance Advisors LLC
Farther Finance Advisors LLC increased its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 6.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,372 shares of the biotechnology company’s stock after acquiring an additional 307 shares during the quarter. Farther Finance Advisors […] - 2025-06-20 07:26:51
Ritholtz Wealth Management Takes $740,000 Position in Exelixis, Inc. (NASDAQ:EXEL)
Ritholtz Wealth Management purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 20,044 shares of the biotechnology company’s stock, valued at approximately $740,000. Several other institutional investors and hedge […] - 2025-06-19 07:58:54
Yousif Capital Management LLC Has $3.69 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)
Yousif Capital Management LLC decreased its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 4.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 99,925 shares of the biotechnology company’s stock after selling 4,465 shares during the period. Yousif […] - 2025-06-13 08:20:52
Wealth Enhancement Advisory Services LLC Sells 76,705 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Wealth Enhancement Advisory Services LLC decreased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 53.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,842 shares of the biotechnology company’s stock after selling 76,705 shares during the period. Wealth […] - 2025-06-06 10:22:48
Exelixis (NASDAQ:EXEL) Price Target Raised to $46.00 at Bank of America
Exelixis (NASDAQ:EXEL – Free Report) had its price target lifted by Bank of America from $45.00 to $46.00 in a research report report published on Thursday morning,Benzinga reports. The brokerage currently has a neutral rating on the biotechnology company’s stock. Several other analysts have also weighed in on EXEL. JMP Securities reissued a “market outperform” […] - 2025-06-06 07:58:52
Exelixis, Inc. (NASDAQ:EXEL) Receives Average Recommendation of “Hold” from Analysts
Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) have been assigned an average rating of “Hold” from the nineteen ratings firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and eleven have assigned a buy recommendation to the […] - 2025-06-04 07:52:46
Exelixis, Inc. (NASDAQ:EXEL) Stake Cut by Royal Bank of Canada
Royal Bank of Canada cut its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 26.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 453,142 shares of the biotechnology company’s stock after selling 167,127 shares during the period. Royal Bank of Canada’s holdings in Exelixis were worth $15,090,000 as of its most […] - 2025-05-27 08:42:49
Balyasny Asset Management L.P. Boosts Stake in Exelixis, Inc. (NASDAQ:EXEL)
Balyasny Asset Management L.P. increased its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 1.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,203 shares of the biotechnology company’s stock after buying an additional 317 shares during the period. Balyasny […] - 2025-05-16 09:38:54
Bank of America Corp DE Purchases 86,307 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Bank of America Corp DE grew its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 7.6% during the fourth quarter, HoldingsChannel reports. The firm owned 1,214,689 shares of the biotechnology company’s stock after buying an additional 86,307 shares during the quarter. Bank of America Corp DE’s holdings in Exelixis were worth $40,449,000 as of […] - 2025-05-16 09:38:53
Exelixis Target of Unusually High Options Trading (NASDAQ:EXEL)
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors purchased 3,627 call options on the company. This represents an increase of approximately 111% compared to the average volume of 1,719 call options. Wall Street Analysts Forecast Growth EXEL has been the topic of several recent […] - 2025-05-15 05:58:52
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Ameriprise Financial Inc.
Ameriprise Financial Inc. cut its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 41.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 933,675 shares of the biotechnology company’s stock after selling 657,315 shares during the quarter. Ameriprise Financial Inc. […] - 2025-05-14 08:03:02
Exelixis, Inc. (NASDAQ:EXEL) Receives $37.59 Consensus Price Target from Analysts
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) has been given a consensus rating of “Hold” by the nineteen research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and eleven have given a buy recommendation to the company. The average […] - 2025-05-13 05:44:54
Exelixis Reaches Analyst Target Price
In recent trading, shares of Exelixis Inc (Symbol: EXEL) have crossed above the average analyst 12-month target price of $37.15, changing hands for $37.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuati - 2025-04-25 11:00:40
Barclays PLC Increases Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)
Barclays PLC grew its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 8.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 348,009 shares of the biotechnology company’s stock after buying an additional 28,420 shares during the period. Barclays PLC […] - 2025-04-22 08:47:07
Exelixis, Inc. (NASDAQ:EXEL) Receives $37.59 Average Target Price from Brokerages
Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the twenty brokerages that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company. […] - 2025-04-18 05:28:59
Bank of Montreal Can Has $3.13 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)
Bank of Montreal Can cut its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 10.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 93,921 shares of the biotechnology company’s stock after selling 10,464 shares during the quarter. Bank of Montreal Can’s holdings in Exelixis were worth $3,128,000 as of its most recent […] - 2025-04-16 08:31:00
Fmr LLC Has $98.16 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)
Fmr LLC lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 19.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,947,599 shares of the biotechnology company’s stock after buying an additional 485,527 shares during the quarter. Fmr […] - 2025-04-16 07:34:56
Cerity Partners LLC Buys 45,890 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Cerity Partners LLC grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 163.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 73,884 shares of the biotechnology company’s stock after acquiring an additional 45,890 shares during the quarter. Cerity Partners LLC’s […] - 2025-04-16 07:34:54
LPL Financial LLC Acquires 22,370 Shares of Exelixis, Inc. (NASDAQ:EXEL)
LPL Financial LLC lifted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 26.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 107,212 shares of the biotechnology company’s stock after acquiring an additional 22,370 shares during the quarter. LPL Financial LLC’s […] - 2025-04-11 07:50:51
Alliancebernstein L.P. Sells 14,245 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Alliancebernstein L.P. lessened its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 3.5% during the fourth quarter, HoldingsChannel reports. The firm owned 390,775 shares of the biotechnology company’s stock after selling 14,245 shares during the period. Alliancebernstein L.P.’s holdings in Exelixis were worth $13,013,000 as of its most recent filing with the Securities and […] - 2025-04-10 08:28:58
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by JPMorgan Chase & Co.
JPMorgan Chase & Co. lowered its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 25.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,314,575 shares of the biotechnology company’s stock after selling 1,116,078 shares during the quarter. JPMorgan Chase […] - 2025-04-03 09:09:17
American Century Companies Inc. Sells 47,750 Shares of Exelixis, Inc. (NASDAQ:EXEL)
American Century Companies Inc. cut its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 10.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 415,865 shares of the biotechnology company’s stock after selling 47,750 shares during the quarter. American Century Companies […] - 2025-04-02 08:24:55
Mitsubishi UFJ Trust & Banking Corp Reduces Stock Position in Exelixis, Inc. (NASDAQ:EXEL)
Mitsubishi UFJ Trust & Banking Corp trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 3.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 92,009 shares of the biotechnology company’s stock after selling 3,657 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Exelixis were worth $3,064,000 […] - 2025-04-01 07:58:53
Thrivent Financial for Lutherans Reduces Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)
Thrivent Financial for Lutherans reduced its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 1.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 74,233 shares of the biotechnology company’s stock after selling 1,451 shares during the quarter. Thrivent Financial for Lutherans’ holdings in […] - 2025-03-28 08:28:50
Corient Private Wealth LLC Has $1.52 Million Position in Exelixis, Inc. (NASDAQ:EXEL)
Corient Private Wealth LLC raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 111.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 45,799 shares of the biotechnology company’s stock after acquiring an additional 24,108 shares during the quarter. Corient Private […] - 2025-03-26 08:40:47
Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and eleven have assigned a buy recommendation to […] - 2025-03-26 06:57:00
Natixis Advisors LLC Buys 31,737 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Natixis Advisors LLC grew its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 109.0% in the fourth quarter, Holdings Channel reports. The fund owned 60,850 shares of the biotechnology company’s stock after acquiring an additional 31,737 shares during the quarter. Natixis Advisors LLC’s holdings in Exelixis were worth $2,026,000 at the end of the […] - 2025-03-25 07:56:50

EXEL institutional holdings

The following institutional investment holdings of EXEL have been identified

Date ETF ISIN/Name Num Shares Book value
2025-06-23 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 155,690USD 6,752,275
2025-06-23 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 40,879USD 1,772,922
2025-06-23 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 340,779USD 14,779,585
2025-06-23 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 135,265USD 5,866,443
2025-06-23 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 135,265USD 5,866,443
2025-06-23 IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF) 2,855USD 123,821
2025-06-23 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 1,036USD 44,931 6.9%
2025-06-23 IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF) 750USD 32,528
2025-06-23 IE000KJPDY61 (iShares World Equity High Income UCITS ETF USD Inc) 1,497USD 64,925
2025-04-29 IE000WHL2ZK1 (iShares U.S. Equity High Income UCITS ETF USD Inc) 6 -3,716.7%USD 231 -3,710.8%
2025-06-23 IE000D8XC064 (iShares World Equity Enhanced Active UCITS ETF USD (Acc)) 292USD 12,664
Total =814,314 USD 35,316,768
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.